Invivyd, Inc. (NASDAQ:IVVD) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$125M · US$2.5 a share · Cantor +1 Dealers: Cantor (lead), H.C. Wainwright & Co. Use of proceeds: Commercial preparedness for potential VYD2311 launch, R&D on RSV and measles programs, SPEAR Study Group efforts, working capital and general corporate purposes | Nov 18, 2025 |
| At-the-market programme of at-the-market (ATM) offering facility Closed: US$29.8M raised | Nov 6, 2025 |
| Public offering of common stock and pre-funded warrants Closed: US$57.5M raised · US$0.52 a share · Cantor Dealers: Cantor (lead) Buyers: RA Capital Management; Janus Henderson Investors Use of proceeds: VYD2311 clinical program, RSV and measles pipeline R&D, SPEAR Study Group efforts, working capital and general corporate purposes | Aug 22, 2025 |